Daphne Quimi Receives Stock Award at Amicus Therapeutics Inc (FOLD) — SEC Form 4, Jan 19, 2022
SEC Form 4 · No Market Transaction
Stock Award
Compensation grant — no market purchase or sale.
Equity Position
369K sh
350,749 → 368,746
Equity Change
+5.1%
shares held after vs before
Filing Lag
2 business days
within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Reporting Owner
| Name | Relationship |
|---|---|
| Daphne Quimi CIK 0001543031 |
CFO
|
Daphne Quimi at Amicus Therapeutics Inc
Full insider history
Bought (12 mo)
—
Sold (12 mo)
—
More from this insider at Amicus Therapeutics Inc
| 2023-01-19 | Sell | -$152,444 | View |
| 2023-01-13 | Award | — | View |
| 2023-01-06 | - | — | View |
| 2023-01-04 | Award | — | View |
| 2022-09-06 | Sell | -$49,621 | View |
Non-Derivative Securities Transactions
| Title | Date | Type | Shares | Price | Net Total | Post-Txn | Ownership |
|---|---|---|---|---|---|---|---|
| Common StockF1 | 2022-01-14 | A - Award/Grant | 36,840 A | — | 368,746 | Direct | |
| Common Stock | 2022-01-14 | F - Tax Payment | 18,843 D | $10.53 | -$198,417 | 349,903 | Direct |
Footnotes (1)
- F1
- Granted for the achievement of the 2019 PRSU TSR goal as determined by the Board of Directors. Show more
Related filings at Amicus Therapeutics Inc
Institutional Holders
13F holders · Jun 30, 2026
2
institutional managers reporting a position
Largest by reported value
- Ifp Advisors, Inc $11.5K
- Huntington National Bank $14
5%+ Holders · 13D/G
5 filers
-
Barclays Plc 5.7%
-
Ubs Group Ag 5.5%
-
Glazer Capital, Llc 0.0%
-
Black Rock, Inc. 7.4%
Other insiders at Amicus Therapeutics Inc
GET /v1/forms/4/0001209191-22-003818
API docs
View Original SEC Filing